Frost & Sullivan Award
Stem cells hold great promise for both cell-based research and advances in the understanding of diseases, with the subsequent development of new drugs and therapies. Frost & Sullivan feels that newer developments involving MSCs with the aim to provide novel solutions for stem cell research and therapeutics are crucially needed.
Vitro Biopharma is a biotechnology company focused on the development and commercialization of adult stem cell technology for applications in stem cell research, drug development, and cell-based therapeutics to treat a variety of diseases and conditions. The company presently offers a series of tools and technologies to promote the development of stem cell research and clinical applications focusing on mesenchymal stem cells. Vitro Biopharma’s current operational strategy is aimed at increasing the market penetration of its proprietary MSC-based research products, while extending its stem cell segment to include differentiated cells derived from MSCs, such as chondrocytes, endothelial cells, and osteoblasts, ideally prescribed for high throughput screening in drug discovery and development.